Výsledky vyhledávání - "Mathieu Allez"

Defining and Assessing the Reproducibility of Crohn’s Disease Endoscopic Lesions: A Delphi-like Method from the GETAID

Publikováno v: Journal of Crohn's and Colitis
Journal of Crohn's and Colitis, 2021, 15 (6), pp.1000-1008. ⟨10.1093/ecco-jcc/jjaa250⟩

Background and Aims Defining and assessing the reproducibility of Crohn’s disease [CD] endoscopic lesions is essential in assessing endoscopic healing. Methods Twelve endoscopic CD experts from the GETAID defined aphthoid erosions [AE], superficial

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c669fa6b5227e0f11920159dcfca1041
https://doi.org/10.1093/ecco-jcc/jjaa250

Zobrazit plný text záznamu

OP12 Blood proteins related to immunoregulation or cellular junctions reveal distinct biological profiles associated with the risk of short-term versus mid/long-term relapse in Crohn’s Disease patients stopping infliximab

Autor: Edouard Louis, Nicolas Pierre, Mathieu Allez, Marie-Alice Meuwis, Y. Bouhnik, D. Laharie, Arnaud Bourreille, J.-F. Colombel, Vân Anh Huynh-Thu

Publikováno v: Journal of Crohn's and Colitis. 15:S011-S013

Background In Crohn’s disease (CD), biologics can induce mucosal healing and stable remission. After reaching this target, treatment de-escalation could be considered but the risk of relapse needs to be estimated. Current biomarkers used to predict

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::1e69e826d9aa93bc39e02d1a26da4cf1
https://doi.org/10.1093/ecco-jcc/jjab075.011

Zobrazit plný text záznamu

DOP80 Effectiveness of ustekinumab and vedolizumab in patients with Crohn’s disease refractory to anti-tumour necrosis factor: A multi-centre comparative study

Autor: H Alric, Julien Kirchgesner, Mathieu Allez, Antoine Meyer, Xavier Treton, Laurent Beaugerie, Yoram Bouhnik, F. Carbonnel, Aurelien Amiot

Publikováno v: Journal of Crohn's and Colitis. 14:S118-S120

Background There is no head-to-head trial comparing ustekinumab and vedolizumab in patients with Crohn’s disease (CD) refractory to anti-TNF. In France between May 2014 and November 2016, vedolizumab (and not ustekinumab) was reimbursed for patient

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::0035f948004df9fc0ded61f3c9df3df4
https://doi.org/10.1093/ecco-jcc/jjz203.119

Zobrazit plný text záznamu

Vedolizumab Clinical Decision Support Tool Predicts Efficacy of Vedolizumab But Not Ustekinumab in Refractory Crohn's Disease

Autor: Franck Carbonnel, Aurelien Amiot, Antoine Meyer, Yoram Bouhnik, Hadrien Alric, Mathieu Allez, Laurent Beaugerie, Xavier Treton, Julien Kirchgesner

Publikováno v: Inflammatory bowel diseases. 28(2)

Introduction Vedolizumab clinical decision support tool (VDZ-CDST) predicts response to vedolizumab, but whether this tool also predicts efficacy of other drugs in Crohn’s disease (CD) is unknown. This study aimed to assess the value of VDZ-CDST to

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5754b7af83b2b4f5aa71f113fdec92ab
https://pubmed.ncbi.nlm.nih.gov/33847351

Zobrazit plný text záznamu

Impact of an Education Program on Ibd Patient’s Skills: Results of A Randomized Controlled Multicenter Study (Ecipe)

Publikováno v: Journal of Crohn's and Colitis
Journal of Crohn's and Colitis, Elsevier-Oxford University Press, 2020, ⟨10.1093/ecco-jcc/jjaa195⟩

Background Better patient knowledge on inflammatory bowel disease [IBD] could improve outcome and quality of life. The aim of this study was to assess if an education programme improves IBD patients’ skills as regards their disease. Methods The GET

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1adbeadbcbab8a08c8bed0bec2eaccec
https://hal-normandie-univ.archives-ouvertes.fr/hal-02964444

Zobrazit plný text záznamu

The outcome of Crohn's disease patients refractory to anti-TNF and either vedolizumab or ustekinumab

Autor: Liza Kassouri, Yoram Bouhnik, Franck Carbonnel, Xavier Treton, Mathieu Allez, Laurent Beaugerie, Aurelien Amiot, Julien Kirchgesner, Antoine Meyer

Publikováno v: Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver. 52(10)

Aims The aims of this study were to describe outcomes in patients with Crohn's disease who fail anti-tumor necrosis factor (TNF) and either vedolizumab or ustekinumab. Methods Multicenter, retrospective study of 100 patients with Crohn's disease who

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2edfb8cc7f5affb94c4ca72830c59328
https://pubmed.ncbi.nlm.nih.gov/32828693

Zobrazit plný text záznamu

OP02 Ustekinumab versus adalimumab for induction and maintenance therapy in Moderate-to-Severe Crohn’s Disease: The SEAVUE study

Autor: A Greenspan, W J Sandborn, Mathieu Allez, O Shchukina, Remo Panaccione, Stephen B. Hanauer, Long-Long Gao, Tanja Kuehbacher, Ellen Scherl, Peter M. Irving, J Izanec, Bruce E. Sands, Christopher Gasink, Silvio Danese, Edward V. Loftus, Vipul Jairath, James D. Lewis, T Hoops, Emese Mihály

Publikováno v: Journal of Crohn's and Colitis. 15:S001-S002

Background We studied the efficacy and safety of ustekinumab (UST) vs adalimumab (ADA) through 1 year in biologic-naïve patients (pts) with moderate-to-severe Crohn’s disease. Methods SEAVUE was a multicenter, randomized, blinded, parallel-group,

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::d5f08709414e9d7ef636029cf2f562e8
https://doi.org/10.1093/ecco-jcc/jjab075.001

Zobrazit plný text záznamu

OP04 Long-term outcomes after ileocolonic resection in Crohn’s disease according to the severity of early endoscopic recurrence

Autor: M L Tran Minh, Claire Auzolle, Lionel Le Bourhis, Benjamin Pariente, Xavier Treton, P. Seksik, Mathurin Fumery, A Buisson, Stéphane Nancey, Nassim Hammoudi, Gilles Boschetti, Madeleine Bezault, Mathieu Allez

Publikováno v: Journal of Crohn's and Colitis. 14:S004-S005

Background Early ileocolonoscopy within the first year after surgery is the gold standard to evaluate post-operative recurrence after ileocolonic resection for Crohn’s disease (CD). The aim of the study was to evaluate the association between lesio

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e3705254d7015841dabe6f595a41e127
https://doi.org/10.1093/ecco-jcc/jjz203.003

Zobrazit plný text záznamu

DOP06 Non-invasive identification of adherent-invasive E. coli in patients with Crohn’s disease

Autor: Stéphane Nancey, Stéphanie Rodriguez, Nicolas Barnich, Xavier Hébuterne, N Ballet, Emilie Vazeille, Mathieu Allez, Bruno Pereira, Elisabeth Billard, Mathurin Fumery, P. Seksik, A Buisson, L Peyrin-Biroulet, Benjamin Pariente

Publikováno v: Journal of Crohn's and Colitis. 14:S044-S045

Background Medications limiting the adhesion of ‘adherent and invasive E. coli’ (AIEC) represent potential strategies to treat Crohn’s disease (CD). However, the ileal AIEC identification is a time-consuming procedure, and the number of AIEC st

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::b24b83b2994d13e96d2190cb5952f9ef
https://doi.org/10.1093/ecco-jcc/jjz203.045

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání